Cholera Vaccine Investment Strategy in Bangladesh

Learn more about:
Related Clinical Trial
Preventative Intervention for Cholera for 7 Days Impact Study of Cholera Vaccination in Endemic Areas – Clinical Surveillance Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults PXVX0200 (CVD103-HgR) vs Shanchol in Mali Cholera-Hospital-Based-Intervention-for-7-days A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi Single Dose Azithromycin in the Treatment of Adult Cholera Safety and Immunogenicity of a New Formulation of Euvichol® Cholera Anti-Secretory Treatment Trial PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Zinc Supplementation in Cholera Patients Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Pilot Introduction of Oral Cholera Vaccine in Orissa, India Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Immunity to Human Cholera in Bangladesh Ciprofloxacin Multiple Dose for Adult Cholera Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo Protective Immunity to Human Cholera in Bangladesh Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Oral Cholera Vaccine Delivery in Rural Bangladesh Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Mass Oral Cholera Vaccination in Zanzibar Cholera Vaccine Investment Strategy in Bangladesh Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Introduction of Cholera Vaccine in Bangladesh Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Evaluation of a Boosting Regimen With Oral Cholera Vaccine Single Dose Azithromycin to Prevent Cholera in Children Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Brief Title

Cholera Vaccine Investment Strategy in Bangladesh

Official Title

Targeted Vaccination of Children in Urban Slums Against Cholera: Evaluation of a Potentially Cost-effective and Impactful Strategy for Deploying Oral Cholera Vaccine in Bangladesh

Brief Summary

      To evaluate the preventive impact, demand, acceptability, uptake, feasibility, and
      cost-effectiveness of a two-dose regimen of the OCV Shanchol in children living in urban
      slums in Bangladesh, Investigators will conduct a targeted mass immunization programme, using
      an innovative approach successfully deployed by the Bangladesh government in its recent
      countrywide campaign of MR vaccination of 52 million children aged 9 months to 14 years (<15
      years). Investigators will undertake a census of a geographic population of approximately
      300,000 persons, with GIS locations of each household. This census will be updated every 6
      months during the follow-up period to permit tracking of births, deaths, and migrations,
      including changes in location of each individual's residence. Following the initial census,
      the OCV will be offered to all non-pregnant individuals aged 1 to 14 years. Operational
      research and economic studies will evaluate the coverage, feasibility, acceptability, demand,
      costs and cost-effectiveness of this vaccination programme.

Detailed Description

      Burden: Cholera remains a major global problem, resulting in more than 100,000 deaths and
      several million cases annually , mostly children. Vaccination has been reconsidered as a key
      component of the public health response to cholera. Bangladesh has one of the world's highest
      burdens of endemic cholera, with an estimated 300,000 cholera cases and over 4,500 deaths
      annually, and with high caseloads and frequent outbreaks in more than half of the country.
      The endemicity of cholera in Bangladesh is demonstrated by the predictable yearly occurrence
      of the disease in the country's high-risk districts and the repetitive seasonal pattern of
      cholera outbreaks, either in spring or autumn, or both .

      Knowledge gap: More evidence is needed to address uncertainties around the cholera disease
      burden, as well as the impact, feasibility, and cost-effectiveness of various vaccination
      strategies against cholera, to add to the existing knowledge base. A special need for
      acquiring field evidence of these vaccine attributes in settings with endemic cholera, which
      account for a very large fraction of the global cholera disease burden, is also recognized .

      Relevance: Nonetheless, the assertion that selective vaccination of children with OCV is an
      impactful approach to controlling cholera at the population level rests on unproven
      assumptions, since there are no studies that directly address this vaccination strategy.
      Therefore, further study on whether targeted mass immunization can create efficiencies that
      general mass immunization would not, is warranted. The Investigators therefore believe that
      the most compelling question for the control of endemic cholera in Bangladesh is how
      targeting 1-14 year olds in urban slums, using the established platform of targeted mass
      childhood immunization recently deployed by the GOB for measles-rubella (MR) vaccine, impacts
      on the overall burden of cholera in the population and how feasible and cost-effective this
      strategy is. Addressing these questions will add to the evidence base on the most cost
      efficient and effective settings and strategies for use of OCV to control endemic disease and
      optimize health impact.

      Hypothesis : Vaccination of children under 15 years of age in urban slums of Dhaka will
      confer at least 50% overall protection to the entire population through combined direct and
      indirect protective effects and it will be cost effective.

      Objectives:To evaluate the feasibility, efficiency, and impact of a two-dose regimen of the
      oral cholera vaccine (OCV) Shanchol delivered to children aged 1-14 years residing in urban
      slums, leveraging a targeted mass immunization delivery platform used for other vaccines in

      Methods: Observational design based on the contrast of persons who do and do not get
      vaccinated according to public health practice(Age-targeted mass immunization program).

Study Type


Primary Outcome

Number of participants with two doses of oral cholera vaccine (Shanchol) will get protection

Secondary Outcome

 Cholera vaccine coverage






* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 1, 2016

Completion Date

October 31, 2019

Primary Completion Date

October 31, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  All healthy, consenting, non-pregnant (as ascertained by history) residents of a high
             risk group, 1 to 14 years of age, of the study area will be included in the study.

        Exclusion Criteria:

          -  Aged less than 1 year and more than 14 years

          -  History of intake of any cholera vaccine

          -  Pregnant women (identified through verbal screening)




1 Year - 14 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


Dr. Firdausi Qadri, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

International Centre for Diarrhoeal Disease Research, Bangladesh


 Gavi, The Vaccine Alliance

Study Sponsor

Dr. Firdausi Qadri, PhD, Principal Investigator, International Centre for Diarrhoeal Disease Research, Bangladesh

Verification Date

December 2019